Cristália will expand production

The Brazilian laboratory Cristália, which operates an industrial complex farmoquímico, pharmaceutical and biotechnology in Itapira, São Paulo State, will expand the production capacity in 2015, with investments of r $ 220 million that are already underway, and expand the portfolio of medicines, from the launch of new products and incorporation of lines, through acquisitions.
With these initiatives, said the amount the President and one of the founders of the pharmaceutical, Ogari Pacheco, the high projection of 11% of revenues, for more than $ 1.6 billion next year, can be reached. "It is ambitious, but we have reasons to think like that," he said. You can also contribute to the expansion of business to another signature technology transfer agreement for a company abroad. The first contract, the lab and Brazil, was announced this year, with a Mexican industry of medical articles, in the area of anti-retroviral drugs-the Cristália is the main producer of the anti-Aids cocktail in the country.
With annual output of 2.108 billion units per year, between tablets, ampoules, ointments, liquids and fractionated, the Cristália is expanding the ability of farmoquímica (inputs), with start-up scheduled for 2015, and erecting two new factories: a cancer and other active principles of peptides, compounds that are not produced in the country.
According to Pacheco, the two plants should begin to produce in 2016. "About 30% of medicines consumed in the country are imported ready [with] and one of the fields where this occurs is in Oncology," said.
At the same time will assess the incorporation of new lines of drugs, via acquisition, the pharmacist also invests in product launches own-"more than 10" next year-and in the expansion of exports, using the structure of a related company in Argentina to grow in the international market of Oncology.
So far, at least six releases are already confirmed: an adjunct anesthetic, an antiviral used to treat infections, a medicine in Oncology area, two in dermatological area and a vitamin (also in dermatology).
Owner of 75 patents, with 152 orders placed, the pharmacist is expected to grant new records in 2015. One of which are anticipated with some anxiety involves biotechnology, a field in which the country's latest ", as the President of Cristália, and intended a world patent: the enzyme collagenase produced with micro-organisms grown in culture based on vegetable proteins, and not animals-as in the traditional method used in producer countries and the pharmaceutical itself.
"Virtually, the risk of transmission of mad cow disease ceases to exist, which opens a huge export potential of collagenase for Europe", commented. The enzyme is used in manufacturing of ointments for treating wounds, burns and necrotized tissues.
According to Pacheco, the four pillars that underpin the laboratory's business (hospital, Government bids, farma and PDPs) contributed to the revenue growth in 2014. Main Division of Cristália, the hospital grew up in 2014 between 13% and 15%, above the industry average, reinforcing the presence in Brazilian hospitals (which already achieves 95%) and index.
The area of governmental sales by bidding, in turn, followed the rhythm of the hospital business this year and Division farma (retail), which represents between 12% and 13% of revenues, grew by over 20%.
Already the business developed through PDPs (acronym for Productive Development Partnerships), federal government program that involves public and private laboratories, including foreign capital, advanced in volume during 2014, but revenue did not show the same speed of expansion. "There has been significant price reductions," says Pacheco.